BGPartner with Novo Holdings and LifeArc on GlycoEra’s funding
BGPartner advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss legal matters and the negotiations of GlycoEra’s financing round. The Swiss biotechnology company, closed a USD 130 million Series B funding.
The context
Investor Novo Holdings led the operation, with saw participation from additional new investors LifeArc Ventures, Catalio Capital Management, QIA, MP Healthcare Venture Management, Sixty Degree Capital and Agent Capital. Existing investors, including Sofinnova Partners, 5AM Ventures, Roche Ventures, and Bristol Myers Squibb, also took part to the round.
Max Klement (partner of Novo Holdings), Matthew Hobson (principal of Catalio Capital Management) and Sohaib Mir (partner at LifeArc Ventures) will enter GlycoEra’s board of directors as new members.
The BGPartner team
The BGPartner team included partner Oliver Gnehm (pictured) and senior associate Victoria Marty, as well as associates Tessa Douma and Anja Spahni.
